Clinical trial · no report yet · Phase 2
IBEX
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- NCT06107738 ↗
- Recruiting
- Barbara Ann Karmanos Cancer Institute
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide; Daratumumab/rHuPH20 Co-formulation
- Arms
- Iberdomide and Daratumumab · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Rate of MRD (-) at 12 months
- Sponsor
- Barbara Ann Karmanos Cancer Institute with Bristol-Myers Squibb, Janssen Pharmaceuticals, Multiple Myeloma Research Consortium
- Start
- Dec 21, 2023
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06107738 · updated Jun 26, 2026